U.S. FDA designates Hanmi Pharm’s LAPSGlucagon Analog as orphan drug

LAPSGlucagon Analog(HM15136) that Hanmi Pharm is developing as a congenital hyperinsulinemia treatment has been recognized as an orphan drug from the U.S. FDA on the 1^st.

The Orphan Drug Designation program by the FDA is a system to support for smooth development and approval process for insurable, life-threatening disease treatments. Once a drug is approved by the program for the first time a...